Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial

William G Christen, Robert J Glynn, J Michael Gaziano, Amy K Darke, John J Crowley, Phyllis J Goodman, Scott M Lippman, Thomas E Lad, James D Bearden, Gary E Goodman, Lori M Minasian, Ian M Thompson Jr, Charles D Blanke, Eric A Klein, William G Christen, Robert J Glynn, J Michael Gaziano, Amy K Darke, John J Crowley, Phyllis J Goodman, Scott M Lippman, Thomas E Lad, James D Bearden, Gary E Goodman, Lori M Minasian, Ian M Thompson Jr, Charles D Blanke, Eric A Klein

Abstract

Importance: Observational studies suggest a role for dietary nutrients such as vitamin E and selenium in cataract prevention. However, the results of randomized clinical trials of vitamin E supplements and cataract have been disappointing and are not yet available for selenium.

Objective: To test whether long-term supplementation with selenium and vitamin E affects the incidence of cataract in a large cohort of men.

Design, setting, and participants: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) Eye Endpoints Study was an ancillary study of the Southwest Oncology Group-coordinated SELECT, a randomized placebo-controlled 4-arm trial of selenium and vitamin E conducted among 35,533 men, 50 years and older for African American participants and 55 years and older for all other men, at 427 participating sites in the United States, Canada, and Puerto Rico. A total of 11,267 SELECT participants from 128 SELECT sites participated in the SELECT Eye Endpoints ancillary study.

Interventions: Individual supplements of selenium (200 μg per day from L-selenomethionine) and vitamin E (400 IU per day of all rac-α-tocopheryl acetate).

Main outcomes and measures: Incident cataract was defined as a lens opacity, age related in origin, and responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-reports confirmed by medical record review. Cataract extraction was defined as the surgical removal of an incident cataract.

Results: During a mean (SD) of 5.6 (1.2) years of treatment and follow-up, 389 cases of cataract were documented. There were 185 cataracts in the selenium group and 204 in the no selenium group (hazard ratio, 0.91; 95 % CI, 0.75-1.11; P = .37). For vitamin E, there were 197 cases in the treated group and 192 in the placebo group (hazard ratio, 1.02; 95 % CI, 0.84-1.25; P = .81). Similar results were observed for cataract extraction.

Conclusions and relevance: These data from a large cohort of apparently healthy men indicate that long-term daily supplementation with selenium and/or vitamin E is unlikely to have a large beneficial effect on age-related cataract.

Trial registration: ClinicalTrials.gov Identifier: NCT00784225.

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Gaziano reported receiving study support and a speaking honorarium from Pfizer related to vitamins. No other authors reported financial disclosures.

Figures

Figure 1
Figure 1
The CONSORT flow diagram for the SELECT Eye Endpoints (SEE) Study. Primary comparisons were to examine the main effects of the SELECT study supplements (selenium vs. no selenium; vitamin E vs. no vitamin E) on occurrence of cataract.
Figure 2
Figure 2
Cumulative incidence rates of cataract and cataract extraction by randomized selenium (2a) and vitamin E (2b) assignment in the SELECT Eye Endpoints (SEE) Study.
Figure 2
Figure 2
Cumulative incidence rates of cataract and cataract extraction by randomized selenium (2a) and vitamin E (2b) assignment in the SELECT Eye Endpoints (SEE) Study.

Source: PubMed

3
Abonnere